Coronado - Quartalszahlen - Good news - 500 Beiträge pro Seite
eröffnet am 16.11.00 21:39:01 von
neuester Beitrag 08.05.01 18:32:32 von
neuester Beitrag 08.05.01 18:32:32 von
Beiträge: 9
ID: 303.063
ID: 303.063
Aufrufe heute: 1
Gesamt: 449
Gesamt: 449
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 43 Minuten | 6411 | |
| vor 1 Stunde | 5138 | |
| vor 48 Minuten | 4245 | |
| heute 18:26 | 3877 | |
| vor 57 Minuten | 2714 | |
| vor 55 Minuten | 1986 | |
| heute 14:53 | 1961 | |
| heute 13:07 | 1512 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.179,69 | +1,39 | 237 | |||
| 2. | 2. | 1,1100 | -19,57 | 110 | |||
| 3. | 3. | 0,1855 | -1,85 | 100 | |||
| 4. | 5. | 9,3400 | +1,03 | 65 | |||
| 5. | 4. | 168,89 | -0,76 | 55 | |||
| 6. | Neu! | 0,4250 | -1,16 | 39 | |||
| 7. | Neu! | 4,7940 | +6,89 | 34 | |||
| 8. | Neu! | 11,905 | +14,97 | 32 |
Feedback
Hallo Freunde der Sonne,
anbei der Quartalsbericht. Grob gesehen, good news, Aktie liegt derzeit in Nasdaq +10%. Kleine Analyse in den nächsten Tagen.
QUARTER ENDING SEPTEMBER 30, 2000
For the quarter ending September 30, 2000 Registrant experienced a net loss of $397,620, which was comprised primarily of its general and administrative expenses of $381,821. 89.2% of Registrant`s 2000 third quarter corporate expenses consisted of officers salaries and wages of $110,413 (28.9%), professional expenses of $58,664 (15.4%) and shareholder services and media promotion of $171,606 (44.9%). In comparison, during the third quarter of the 1999 fiscal year 65.6% of Registrant`s corporate expense of $213,436 consisted of officers salaries of $75,000 (35.1%), professional expenses of $53,985 (25.3%) and shareholder services and media promotion of $11,106 (5.2%). In April 1999 the annual salaries of Registrant`s Chairman and President were increased to $150,000 each and Dr. LiVecchi started receiving an accrued salary of $75,000 in April 2000. Registrant expects its professional expenses in 2000 to remain at a high level as a result of its continuing costs for its FDA application presently estimated at $18, 000 per month.
NINE MONTHS ENDING SEPTEMBER 30, 2000
OPERATIONS. Since Registrant closed its Scottsdale glaucoma treatment center on March 2, 1999, the first three quarters of the 2000 fiscal year can not be compared to the operations for the first three quarters of 1999.
For the nine months ending September 30, 2000 Registrant experienced a net loss of $1,589,828, which was comprised primarily of its general and administrative expenses incurred at the corporate level of $1,537, 071 and net interest expense of $59,334. 89.0% of Registrant`s 2000 first nine months corporate expenses consisted of officers` salaries and wages of $342,261 (22.3%), professional expenses of $307,418 (20.0%) and shareholder services and media promotion of $717,856 (46.7%). In comparison, during the first nine months of 1999 61.4% of Registrant`s corporate expense of $744,598 consisted of officers` salaries of $200,000 (26.9%), professional expenses of $181,860 (24.4%) and shareholder services and media promotion of $74,905 (10.1%). The increase in officers` salaries for 2000 over 1999 occurred as a result of two officers` salary being increased in April 1999 by $50,000 and Dr. LiVecchi receiving an accrued annual salary of $75,000 in April 2000. The increase in professional expenses in 2000 over 1999 occurred as a result of Dr. Bores being involved in the FDA application process full time in 2000 and the increased legal expenses incurred in the FDA application process and listing Registrant`s stock for trading on a German exchange in the first quarter 2000. The increase in shareholder services and media promotion in 2000 over 1999 resulted from an agreement with a new shareholder relations firm being reached in 2000 and the commencement of a European product marketing campaign in the first quarter of 2000. Approximately 80% of the corporate expenses in 2000 were paid with Registrant`s common stock in order to preserve Registrant`s cash resources. Registrant expects its management salaries to increase in the last quarter of 2000 because on April 1, 2000 Dr. LiVecchi was granted an annual salary of $75,000. Registrant expects its professional expenses in 2000 to remain at a high level as a result of its continuing costs for its FDA application presently estimated at $18,000 per month. As Registrant continues its foreign marketing efforts in 2000, its promotional expenses will likely remain high.
During the nine months ended September 30, 2000 Registrant received a total of $125,000 as a non-refundable deposit toward the reduced exercise price of Registrant`s outstanding warrants. That option expired on September 29, 2000 and the deposit has been retained by Registrant.
On October 21, 2000 Registrant executed a one year option agreement with CIBA Vision AG, a Swiss corporation doing business from Atlanta, Georgia ("Ciba Vision"). This agreement permits Ciba Vision to obtain the exclusive worldwide license to the patent rights and technology for Registrant`s PNT product. Ciba Vision will conduct a study, at its cost, of Registrant`s PNT product in Europe in accordance with the study protocol previously agreed to by the parties. It is anticipated that Ciba Vision will submit the study for approval in Italy before 2000 year end and the study will extend for some 120 to 150 days. Registrant will have access to all European clinical study results and it is anticipated Dr. Leo Bores, Registrant`s medical director, will participate in the initial patient procedures in Europe. Ciba Vision will also assist Registrant in its discussion with the FDA in order to lead to the expeditious approval in the United States of PNT as a first line therapy for the treatment of glaucoma. Registrant and Ciba Vision are required by this agreement to negotiate in good faith the exclusive license agreement during the option period. Registrant is hopeful a license agreement will be executed with Ciba Vision in the first half of 2001; however, at this time there is no assurance any definitve license agreement with Ciba Vision will ever by executed by Registrant.
LIQUIDITY AND CAPITAL RESOURCES. On a short-term and long-term basis Registrant requires only minimal capital to sustain its manufacturing of the patented equipment, because of Registrant`s current inventory levels. Because of the Registrant`s cash position at year-end and general and administrative cash expenses totaling approximately $187,620, Registrant suffered from a liquidity shortage during the first half of 2000. Registrant was required to borrow a total of $225, 407 through June 30, 2000 from its two officers, Richard and Gary Smith. Unless substantial product sales are achieved in the near future, Registrant will continue to experience a liquidity shortage. There can be no assurance as to when Registrant`s product will be approved for sale in the United States by the FDA or when foreign sales will commence in a substantial manner. Registrant will likely be forced to borrow additional funding from its management throughout the remainder of 2000; however, there is no assurance Registrant will be able to obtain any financing in the future.
On October 21, 2000 Registrant executed a one year option agreement with CIBA Vision AG, a Swiss corporation doing business from Atlanta, Georgia ("Ciba Vision"). This agreement permits Ciba Vision to obtain the exclusive worldwide license to the patent rights and technology for Registrant`s PNT product. Ciba Vision will conduct a study, at its cost, of Registrant`s PNT product in Europe in accordance with the study protocol previously agreed to by the parties. It is anticipated that Ciba Vision will submit the study for approval in Italy before 2000 year end and the study will extend for some 120 to 150 days. Registrant will have access to all European clinical study results and it is anticipated Dr. Leo Bores, Registrant`s medical director, will participate in the initial patient procedures in Europe. Ciba Vision will also assist Registrant in its discussion with the FDA in order to lead to the expeditious approval in the United States of PNT as a first line therapy for the treatment of glaucoma. Registrant and Ciba Vision are required by this agreement to negotiate in good faith the exclusive license agreement during the option period. Registrant is hopefull a license agreement will be executed with Ciba Vision in the first half of 2001; however, at this time there is no assurance any definitive license agreement with Ciba Vision will ever be executed by Registrant
During the nine months ended September 30, 2000, Registrant received a total of $125,000 as a non-refundable deposit toward the reduced exercise price of Registrant`s outstanding warrants. That option expired on September 30, 2000 and the deposit has been retained by Registrant.
Registrant is hopeful it can acquire one or more assets or companies in 2000 which can provide Registrant with cashflow with which to fund its operations. Registrant would attempt to finance such acquisitions with cash from the exercise of outstanding warrants or its common stock. However, there is no assurance that Registrant will be able to complete any acquisition in the future. Additionally, compliance with state and federal securities laws may make any attempted acquisitions time-consuming and expensive.
On a long-term basis, Registrant anticipates, without assurances, that the sale of its product in the U.S. and internationally will provide sufficient liquidity to the Registrant.
Through September 30, 2000 the Registrant received loans of approximately $112,500 from each of G. Richard Smith and Gary R. Smith, the Registrant`s Chairman and President, respectively. These loans accrue annual interest at the rate of 15%.
(c) 1995-1999 Cybernet Data Systems, Inc. All Rights Reserved.
Received by Edgar Online: Nov. 14, 2000
Tom
anbei der Quartalsbericht. Grob gesehen, good news, Aktie liegt derzeit in Nasdaq +10%. Kleine Analyse in den nächsten Tagen.
QUARTER ENDING SEPTEMBER 30, 2000
For the quarter ending September 30, 2000 Registrant experienced a net loss of $397,620, which was comprised primarily of its general and administrative expenses of $381,821. 89.2% of Registrant`s 2000 third quarter corporate expenses consisted of officers salaries and wages of $110,413 (28.9%), professional expenses of $58,664 (15.4%) and shareholder services and media promotion of $171,606 (44.9%). In comparison, during the third quarter of the 1999 fiscal year 65.6% of Registrant`s corporate expense of $213,436 consisted of officers salaries of $75,000 (35.1%), professional expenses of $53,985 (25.3%) and shareholder services and media promotion of $11,106 (5.2%). In April 1999 the annual salaries of Registrant`s Chairman and President were increased to $150,000 each and Dr. LiVecchi started receiving an accrued salary of $75,000 in April 2000. Registrant expects its professional expenses in 2000 to remain at a high level as a result of its continuing costs for its FDA application presently estimated at $18, 000 per month.
NINE MONTHS ENDING SEPTEMBER 30, 2000
OPERATIONS. Since Registrant closed its Scottsdale glaucoma treatment center on March 2, 1999, the first three quarters of the 2000 fiscal year can not be compared to the operations for the first three quarters of 1999.
For the nine months ending September 30, 2000 Registrant experienced a net loss of $1,589,828, which was comprised primarily of its general and administrative expenses incurred at the corporate level of $1,537, 071 and net interest expense of $59,334. 89.0% of Registrant`s 2000 first nine months corporate expenses consisted of officers` salaries and wages of $342,261 (22.3%), professional expenses of $307,418 (20.0%) and shareholder services and media promotion of $717,856 (46.7%). In comparison, during the first nine months of 1999 61.4% of Registrant`s corporate expense of $744,598 consisted of officers` salaries of $200,000 (26.9%), professional expenses of $181,860 (24.4%) and shareholder services and media promotion of $74,905 (10.1%). The increase in officers` salaries for 2000 over 1999 occurred as a result of two officers` salary being increased in April 1999 by $50,000 and Dr. LiVecchi receiving an accrued annual salary of $75,000 in April 2000. The increase in professional expenses in 2000 over 1999 occurred as a result of Dr. Bores being involved in the FDA application process full time in 2000 and the increased legal expenses incurred in the FDA application process and listing Registrant`s stock for trading on a German exchange in the first quarter 2000. The increase in shareholder services and media promotion in 2000 over 1999 resulted from an agreement with a new shareholder relations firm being reached in 2000 and the commencement of a European product marketing campaign in the first quarter of 2000. Approximately 80% of the corporate expenses in 2000 were paid with Registrant`s common stock in order to preserve Registrant`s cash resources. Registrant expects its management salaries to increase in the last quarter of 2000 because on April 1, 2000 Dr. LiVecchi was granted an annual salary of $75,000. Registrant expects its professional expenses in 2000 to remain at a high level as a result of its continuing costs for its FDA application presently estimated at $18,000 per month. As Registrant continues its foreign marketing efforts in 2000, its promotional expenses will likely remain high.
During the nine months ended September 30, 2000 Registrant received a total of $125,000 as a non-refundable deposit toward the reduced exercise price of Registrant`s outstanding warrants. That option expired on September 29, 2000 and the deposit has been retained by Registrant.
On October 21, 2000 Registrant executed a one year option agreement with CIBA Vision AG, a Swiss corporation doing business from Atlanta, Georgia ("Ciba Vision"). This agreement permits Ciba Vision to obtain the exclusive worldwide license to the patent rights and technology for Registrant`s PNT product. Ciba Vision will conduct a study, at its cost, of Registrant`s PNT product in Europe in accordance with the study protocol previously agreed to by the parties. It is anticipated that Ciba Vision will submit the study for approval in Italy before 2000 year end and the study will extend for some 120 to 150 days. Registrant will have access to all European clinical study results and it is anticipated Dr. Leo Bores, Registrant`s medical director, will participate in the initial patient procedures in Europe. Ciba Vision will also assist Registrant in its discussion with the FDA in order to lead to the expeditious approval in the United States of PNT as a first line therapy for the treatment of glaucoma. Registrant and Ciba Vision are required by this agreement to negotiate in good faith the exclusive license agreement during the option period. Registrant is hopeful a license agreement will be executed with Ciba Vision in the first half of 2001; however, at this time there is no assurance any definitve license agreement with Ciba Vision will ever by executed by Registrant.
LIQUIDITY AND CAPITAL RESOURCES. On a short-term and long-term basis Registrant requires only minimal capital to sustain its manufacturing of the patented equipment, because of Registrant`s current inventory levels. Because of the Registrant`s cash position at year-end and general and administrative cash expenses totaling approximately $187,620, Registrant suffered from a liquidity shortage during the first half of 2000. Registrant was required to borrow a total of $225, 407 through June 30, 2000 from its two officers, Richard and Gary Smith. Unless substantial product sales are achieved in the near future, Registrant will continue to experience a liquidity shortage. There can be no assurance as to when Registrant`s product will be approved for sale in the United States by the FDA or when foreign sales will commence in a substantial manner. Registrant will likely be forced to borrow additional funding from its management throughout the remainder of 2000; however, there is no assurance Registrant will be able to obtain any financing in the future.
On October 21, 2000 Registrant executed a one year option agreement with CIBA Vision AG, a Swiss corporation doing business from Atlanta, Georgia ("Ciba Vision"). This agreement permits Ciba Vision to obtain the exclusive worldwide license to the patent rights and technology for Registrant`s PNT product. Ciba Vision will conduct a study, at its cost, of Registrant`s PNT product in Europe in accordance with the study protocol previously agreed to by the parties. It is anticipated that Ciba Vision will submit the study for approval in Italy before 2000 year end and the study will extend for some 120 to 150 days. Registrant will have access to all European clinical study results and it is anticipated Dr. Leo Bores, Registrant`s medical director, will participate in the initial patient procedures in Europe. Ciba Vision will also assist Registrant in its discussion with the FDA in order to lead to the expeditious approval in the United States of PNT as a first line therapy for the treatment of glaucoma. Registrant and Ciba Vision are required by this agreement to negotiate in good faith the exclusive license agreement during the option period. Registrant is hopefull a license agreement will be executed with Ciba Vision in the first half of 2001; however, at this time there is no assurance any definitive license agreement with Ciba Vision will ever be executed by Registrant
During the nine months ended September 30, 2000, Registrant received a total of $125,000 as a non-refundable deposit toward the reduced exercise price of Registrant`s outstanding warrants. That option expired on September 30, 2000 and the deposit has been retained by Registrant.
Registrant is hopeful it can acquire one or more assets or companies in 2000 which can provide Registrant with cashflow with which to fund its operations. Registrant would attempt to finance such acquisitions with cash from the exercise of outstanding warrants or its common stock. However, there is no assurance that Registrant will be able to complete any acquisition in the future. Additionally, compliance with state and federal securities laws may make any attempted acquisitions time-consuming and expensive.
On a long-term basis, Registrant anticipates, without assurances, that the sale of its product in the U.S. and internationally will provide sufficient liquidity to the Registrant.
Through September 30, 2000 the Registrant received loans of approximately $112,500 from each of G. Richard Smith and Gary R. Smith, the Registrant`s Chairman and President, respectively. These loans accrue annual interest at the rate of 15%.
(c) 1995-1999 Cybernet Data Systems, Inc. All Rights Reserved.
Received by Edgar Online: Nov. 14, 2000
Tom
Ich Danke Dir tom006 auf deine Analyse bin ich gespannt.Tschau
CORONADO ist eine ganz serioese Unternehmung die auch in Frankfurt gelistet ist!!
Habe alles uebrprueft stimmt genau, habe mir auch die Seite von Donner Corp. angesehen. Ich habe 20,0000 gekauft!!
Chart sieht auch gut aus! Aufladen kann ich nur sagen und die Kuh fliegen lassen!!
Habe alles uebrprueft stimmt genau, habe mir auch die Seite von Donner Corp. angesehen. Ich habe 20,0000 gekauft!!
Chart sieht auch gut aus! Aufladen kann ich nur sagen und die Kuh fliegen lassen!!
Beobachte ich schon lange ist demnächst ein Nasdaq Kandidat! Wirklich Gute Company, erstklassig geführt und kommt von $4.00 runter bei $0.23 das wird SUPERGREEN
Trading Spotlight
Coronado Zulassung European Commission ERHALTEN
"Coronado`s Pneumatic Trabeculoplasty (PNT) treatment system has received a CE
mark from the European Commission, allowing it to be marketed throughout
Europe," Donner said. "Coronado is moving forward to conduct a clinical study in
the U.S. to support its 510 (k) application to the U.S. Food and Drug
Administration to allow marketing in America."
"Coronado`s Pneumatic Trabeculoplasty (PNT) treatment system has received a CE
mark from the European Commission, allowing it to be marketed throughout
Europe," Donner said. "Coronado is moving forward to conduct a clinical study in
the U.S. to support its 510 (k) application to the U.S. Food and Drug
Administration to allow marketing in America."
http://ragingbull.lycos.com/mboard/boards.cgi?board=CDIK&rea…
ES..
Auch es gibt die mehrfachen Standorte, die für die NVS-Testsite betrachtet werden. Italien vermutlich ist nicht einer von ihnen. Wahrscheinlicher Standort? Deutschland. Aber wir sehen.
ES..
Auch es gibt die mehrfachen Standorte, die für die NVS-Testsite betrachtet werden. Italien vermutlich ist nicht einer von ihnen. Wahrscheinlicher Standort? Deutschland. Aber wir sehen.
Also Leute,
mich gibt es immer noch, ich stehe immer noch zu Coronado. Habe gestern noch inmal mit R. Smith, dem CEO von Coronado gesprochen.
Die Liquiditätsprobleme sind gelöst, die Studie von Novartis ist positiv ausgegangen, Novartis hat bereits den ersten Betrag bezahlt.
Es gibt nur ein Problem zur Zeit, das auch angesprochen wurde: Durch die niedrige Notierung zur Zeit ist das Unternehmen sehr wenig wert. Es kann deshalb sehr gut sein, dass Novartis hier einfach Coronado übernimmt.
Tom
mich gibt es immer noch, ich stehe immer noch zu Coronado. Habe gestern noch inmal mit R. Smith, dem CEO von Coronado gesprochen.
Die Liquiditätsprobleme sind gelöst, die Studie von Novartis ist positiv ausgegangen, Novartis hat bereits den ersten Betrag bezahlt.
Es gibt nur ein Problem zur Zeit, das auch angesprochen wurde: Durch die niedrige Notierung zur Zeit ist das Unternehmen sehr wenig wert. Es kann deshalb sehr gut sein, dass Novartis hier einfach Coronado übernimmt.
Tom
Hi Topgun,
hast Du die 20,000 zusammen? Mich hat es 1 Woche gekostet, um diese Stücke zu bekommen. Der Markt ist leer.
Heute in USA schon +17%.
Coronado kommt!
Werde heute abend mal kurz auf die Seite der EMEA (Europäische Zulassungsbehörde) schauen, um festzustellen, ob die was gepostet haben.
Tom
hast Du die 20,000 zusammen? Mich hat es 1 Woche gekostet, um diese Stücke zu bekommen. Der Markt ist leer.
Heute in USA schon +17%.
Coronado kommt!
Werde heute abend mal kurz auf die Seite der EMEA (Europäische Zulassungsbehörde) schauen, um festzustellen, ob die was gepostet haben.
Tom
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 237 | ||
| 110 | ||
| 100 | ||
| 65 | ||
| 55 | ||
| 39 | ||
| 34 | ||
| 32 | ||
| 29 | ||
| 25 |
| Wertpapier | Beiträge | |
|---|---|---|
| 22 | ||
| 20 | ||
| 18 | ||
| 18 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 17 | ||
| 17 | ||
| 17 |
